Archive for February 2010

Monitoring country progress




In adopting the 2001 Declaration of Commitment on HIV/AIDS, Member States obligated themselves to regularly report on their progress to the General Assembly. The Secretary-General charged the UNAIDS Secretariat with the responsibility for developing the reporting process, accepting reports from member States on his behalf, and preparing a regular report for the General Assembly. Member States are required to submit Country Progress reports to the UNAIDS Secretariat every two years.
In close collaboration with national governments, UNAIDS Cosponsors and development partners, the UNAIDS Secretariat developed a set of Core Indicators for the monitoring of the Declaration of Commitment for the first round of reporting in 2003. After each subsequent reporting round these indicators have been reviewed and, if necessary, updated, based on an analysis of indicator performance in previous reporting rounds, advice from partners and programmatic developments.

Three rounds of UNGASS Reporting have since taken place in 2004, 2006 and 2008. The UNGASS country response rate has been high from the outset, and has increased significantly subsequently. In 2004, 54% of UN Member States submitted progress reports; that percentage rose to 77% in 2008. The three-year UNGASS data for programme indicators for all countries are graphically illustrated athttp://cfs.indicatorregistry.org/ .
The three-year UNGASS reporting data show limited progress has been made towards the DoC targets:
  • Among youth aged 15-24 years, only 38% of females and 40% of males can demonstrate accurate and sufficient knowledge about ways to protect themselves from acquiring HIV; the UNGASS target is 90% by 2010.
  • Programmes to prevent the transmission of HIV from mother to child currently reach 33% of those in needs: the UNGASS target is 80% by 2010.
  • By 2008, new infections in infants born to HIV-positive mothers had declined by 25% from 2001 levels in hyper-endemic countries; the UNGASS target is a 50% reduction by 2010.
  • On the other hand, financial investment in AIDS responses has increased substantially, and the global target of 10 billion US dollars in 2008 has been met. However, the global economic recession calls into the doubt the sustainability of that achievement.

The UNGASS reporting system that was established for monitoring the Declaration of Commitment contributes significantly to accurately monitor the progress towards the MDG of having halted and reversed the AIDS epidemic by 2015 and having achieved 80% ART coverage by 2010 (MDG6). The UNGASS 2010 Reporting will take place at the ten-year milestone for UNGASS DoC monitoring, when the world is also midway to the 2015 deadline for the MDG, as has the cut-off for Universal Access Initiative adopted by 2006 Political Declaration.
For further technical guidance on UNGASS 2010 Reporting, please refer to 2010 UNGASS Country Reporting

Leave a comment

Confidentiality and Security of HIV Information




As part of scaling-up HIV services, increasing emphasis is being placed on the collection of information to improve patient management and monitoring as well as programme or service monitoring and evaluation. Such data allow individuals to be tracked over time and between places, and enable the development of longitudinal patient-level information for clinical management.

Patient-level information becomes even more important when used for programme or service monitoring or evaluation. This will require information systems, whether paper-based or electronic, which ensure patient confidentiality yet allow relatively easy access to the information at both the individual and aggregate level. Implemented systems must also address issues of system availability.
Using health data of individuals for public health goals must be balanced against individuals’ rights to privacy and confidentiality, and should be based on human rights principles.
When developing approaches to protecting data, a distinction should be made between providing for the physical protection of data to guard against environmental threats, and the protection needed to guard against inappropriate use of sensitive information, whether due to inadvertent or deliberate activities.

Three interrelated concepts have an impact on the development and implementation of protection of sensitive data. These are privacy, confidentiality, and security. While interrelated, each is distinct and each is developed and implemented in a different manner.
Privacy is both a legal and an ethical concept. The legal concept refers to the legal protection that has been accorded to an individual to control both access to and use of personal information and provides the overall framework within which both confidentiality and security are implemented. 

Confidentiality
 relates to the right of individuals to protection of their data during storage, transfer, and use, in order to prevent unauthorized disclosure of that information to third parties. Development of confidentiality policies and procedures should include discussion of the appropriate use and dissemination of health data with systematic consideration of ethical and legal issues as defined by privacy laws and regulations.

Security is a collection of technical approaches that address issues covering physical, electronic, and procedural aspects of protecting information collected as part of the scale-up of HIV services. It must address both protection of data from inadvertent or malicious inappropriate disclosure, and non-availability of data due to system failure and user errors.

Leave a comment

Largest ever HIV vaccine trial results very encouraging


Geneva, 01-03-2010 monday – The World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) are optimistic about the results, announced today, of the largest ever HIV vaccine clinical trial held to date.
The study results, representing a significant scientific advance, are the first demonstration that a vaccine can prevent HIV infection in a general adult population and are of great importance.

The two UN agencies congratulate both the principal investigators, sponsors and the trial volunteers who have made this encouraging result possible.
The RV144 HIV vaccine study results, revealing a 31.2% vaccine efficacy in preventing HIV infections are characterized as modestly protective. However, these results have instilled new hope in the HIV vaccine research field and promise that a safe and highly effective HIV vaccine may become available  for  populations throughout the world who are most in need of such a vaccine. No vaccine safety issues were observed in the trial.
Much more work, though, has to be done by the principal investigators and a large group of international collaborators to analyse the trial data, understand the protective mechanism, determine the duration of protection, and map next steps. Licensure at this point in time may not be possible solely on the basis of this study's results, and it remains to be seen if the two specific vaccine components in this particular regimen would be applicable to other parts of the world with diverse host genetic backgrounds and different HIV subtypes driving different regional sub-epidemics. Once an HIV vaccine does become available, it will need to be universally accessible by all persons at risk.
In addition, early HIV vaccines with modest levels of efficacy would most likely have to be used as complementary tools in combination with strategies to promote changes in behavioural and social norms, promotion of correct and consistent condom use, access to safe injection equipment, as well as male circumcision.
The Phase III trial, involving 16 395 adult male and female volunteers in Thailand, was a test- of-concept of a novel HIV vaccine regimen with two different candidate vaccines developed by Sanofi-Pasteur and the non-profit organization Global Solutions for Infectious Diseases. The trial was performed by the Thai Ministry of Public Health, sponsored by the United States Army Surgeon General and received funding from the United States National Institute for Allergy and Infectious Diseases and the United States Army Medical Research and Materiel Command, Department of Defense. 
WHO and UNAIDS began supportive work for this trial 18 years ago, in 1991, when Thailand was recommended as one of the WHO-sponsored countries in preparation for HIV vaccine trials and the development of the National AIDS Vaccine Plan. In particular, WHO and UNAIDS through their HIV Vaccine Advisory Committee (VAC) provided continuous technical guidance and advice for review, approval and implementation of the RV144 trial protocol. In 2006, VAC performed an external evaluation of the trial examining various ethical and community-related issues: this evaluation showed that the trial was being conducted at the highest scientific and ethical standards and with active community participation.
Moreover, WHO and UNAIDS, in collaboration with partners, such as the Global HIV Vaccine Enterprise have jointly developed numerous policy documents relating to access to care and treatment for trial participants, design and purpose of test of concept HIV vaccine trials as well as scientific parameters.
WHO and UNAIDS will work with the global HIV stakeholder community to further understand and resolve a range of questions related to the potential introduction of an HIV vaccine of moderate protective efficacy. This includes additional, in-depth trials in different populations with diverse host and virus genetic backgrounds.
Until a highly effective HIV vaccine becomes available UNAIDS and WHO underline the importance of effective and proven HIV prevention methods for all people. A comprehensive HIV prevention package includes, but is not limited to, behavioural interventions to reduce sexual risk practices, including correct and consistent male and female condom use, early and effective treatment for sexually transmitted infections, male circumcision in high HIV prevalence settings, harm reduction for injecting drug users, post-exposure prophylaxis with antiretroviral drugs, and interventions to prevent HIV transmission in health care settings. 

Posted in | Leave a comment

dna paternity test in india


Your Specialist DNA Test Provider in India

easyDNA India is your specialist provider of DNA testing offering tests that are accurate and affordable. For your peace of mind, you can rest assured that all our DNA tests are processed through our internationally accredited DNA testing laboratory. To gurantee the accuracy of your DNA test result, all tests are analyzed with the most advanced genetic identification systems on the basis of 16 different genetic markers.
Our most popular test, which is the DNA test for paternity, can exclude with 100% accuracy an individual as the biological father of the child in question. If he is the father, then we will determine this with a probablity of paternity in excess of 99.9999+%. Once we receive your samples at the laboratory, paternity test results will be sent within 5 to 7 working days. You can also select our express option and receive results after 48 hours.
The cost of our accredited paternity test for one child and an alleged father is priced at only INR 10950.This is inclusive of your home DNA test kit to collect the samples, the analysis and the final result. You canOrder directly through our website or else contact our office in Nagercoil directly to process your order. If you do not possess a credit card, the Payment Options page for other forms of payment.
easyDNA also offers a wide range of DNA Relationship Tests for cases where the immediate members of the family are not available. These tests can analyse a range of biological relationships including between Siblings, Aunts/Uncles and Grand-parents. If you want us to advise you which test is more suitable for your case, contact us and we will discuss your case in detail.  
Where it is not possible to obtain a mouth swab using our DNA test kit, testing can also be performed through other type of samples including hair, blood stains, items of clothing and cigarette butts. Visit ourDNA Forensic Testing section for more details including shipping and costs.

DNA Paternity Testing in India through ISO accredited laboratory.

Common Questions on DNA Testing

How to order your DNA test

Step 1: Depending on your case, you need to select the type of test you need from the following: DNA Paternity TestRelationship TestingDNA ProfileTwin Zygosity TestDNA Forensic Test, Ancestry Testand Genetic Predisposition DNA Test.
Step 2:  Payment can be made by credit card - Mastercard or Visa - through the secure Order page. Select the test that you require from the options provided and the number of people participating in the test. Other payment options iare also available.
Step 3: Once your order is confirmed your DNA testing kit will be dispatched. This kit contains everything required for the test including comprehensive instructions. Visit our visual online DNA Sample Collection Guide for information about how to collect your own samples. Please note that the DNA kit is applicable to all DNA tests. For a Legal DNA Test a different sample collection procedure is required.
Step 4: After collecting the samples, you will to send them in the self-addressed envelope provided with your kit. Make sure you include the submission forms correctly filled in.
Step 5: Your samples will be processed once we receive them at the lab and the results will be issued by email within 5-7 working days, unless you select our express option for an additional charge. To view what a result looks like, we have provided a sample DNA Paternity test result online. 

Tips to select a DNA Testing Service Provider

ACCREDITATION: When dealing with this type of testing, make sure that the company you select is using a properly accredited DNA testing laboratory. Make sure your service provider works through a testing lab that is fully accredited.

TECHNICAL SUPPORT: Make sure that the DNA testing company has the experience to offer you the best technical support throughout the entire testing process. The service staff at easyDNA have over 7 years experience dealing with DNA testing.
TESTING 16 GENETIC LOCI: All our DNA tests are tested on 16 loci. Make sure the company you select is offering you the highest quality form of testing and is not testing anything less. We offer you only premium testing as we only believe in the highest standard that is befitting to our laboratory's accreditation status.
...Click here for more DNA testing Tips or for our Frequently Asked Questions or else to order your ownhome paternity test and receive your DNA test kit.
easyDNA India is an India based company operating through our administration office in Nagercoil. The company forms part of easyDNA Limited, an international DNA testing service provider offering high quality, accurate and confidential DNA tests to private and public organisations and individuals throughout the world.

Leave a comment

High Fidelity (HF) Restriction Enzymes



High Fidelity (HF) Restriction Enzymes


overview:
As part of our ongoing commitment to the study and improvement of restriction enzymes, we are pleased to introduce a line of High Fidelity (HF) restriction enzymes. These engineered enzymes have the same specificity as their established counterparts. However, certain properties have been altered, including buffer requirements and enzyme fidelity. These modifications provide customers with more flexibility in setting up their restriction enzyme digests. The overall goal of engineering restriction enzymes is to provide improved enzymes that will allow more flexibility with respect to reaction volume, incubation time and buffer compatibility. Each of these enzymes has been purified to the same high standards as our other restriction enzymes, and are available at the same low price.

The introductory selection of engineered restriction enzymes offers the benefit of reduced star activity. 
Star activity, or relaxed specificity, is an intrinsic property of restriction enzymes. Most restriction enzymes will not exhibit star activity when used under the recommended reaction conditions. However, for enzymes that have reported star activity, extra caution must be taken to set up reactions under the recommended conditions to avoid unwanted cleavage. Different techniques such as cloning, genotyping, mutational analysis, mapping, probe preparation, sequencing and methylation detection employ a wide range of reaction conditions and require the use of enzymes under suboptimal conditions. These new high fidelity (HF) enzymes will offer increased flexibility to reaction setup, maximizing results under a wider range of conditions.
Features:
  • Reduced star activity
  • Single buffer (NEBuffer 4)
  • Time-Saver qualified (digests substrate DNA in 5 minutes)
  • Added flexibility in digest setup
  • No added expense – available at same low price as wild type enzyme
ScaI is one of the most frequently reported
enzymes to exhibit star activity (unwanted
cleavage). While star activity is observed with
ScaI in NEBuffer 3 (supplied buffer) as well
as NEBuffer 4, star activity is significantly
reduced with ScaI-HF. 20 µl reactions
were set up containing 2 µl of enzyme and
incubated for 1 hour. Marker M is the 1 kb
DNA Ladder (
NEB #N3232).

Applications:
  • Cloning 
  • Genotyping
  • Mutational Analysis
  • Mapping
  • Probe Preparation
  • Sequencing
  • Methylation Detection
  • Any application that requires high fidelity or flexible reaction setup
EcoRI from various suppliers produces the correct banding pattern when 10 units are used, however, star activity is observed with larger amounts of enzyme. Star activity is not observed with EcoRI-HF, even at higher enzyme amounts. Reactions were set up according to recommended reaction conditions of each manufacturer. Reactions contained 1 µg Lambda DNA in a 50 µl reaction volume and were incubated overnight at 37°C. Marker M is the 1 kb DNA Ladder (NEB #N3232)
ProductNEB #SIZE
AgeI-HF™R3552S250 units
BamHI-HFR3136S10000 units
BsaI-HF™R3535S1000 units
EagI-HFR3505S500 units
EcoRI-HFR3101S10000 units
EcoRV-HFR3195S4000 units
KpnI-HF™R3142S4000 units
MfeI-HFR3589S500 units
NcoI-HFR3193S1000 units
NheI-HFR3131S1000 units
NotI-HFR3189S500 units
PstI-HF™R3140S10000 units
PvuII-HFR3151S5000 units
SacI-HFR3156S2000 units
SalI-HFR3138S2000 units
SbfI-HFR3642S500 units
ScaI-HFR3122S1000 units
SphI-HFR3182S500 units
SspI-HFR3132S1000 units
StyI-HF™R3500S3000 units




Technical Reference Quick Links
NEBuffer ActivityStar ActivityReduced Star Activities of HF EnzymesDouble DigestionTime-Saver
Qualified Enzymes

Posted in | Leave a comment

DNA sequencing



What is DNA sequencing?


DNA sequencing, the process of determining the exact order of the 3 billion chemical building blocks (called bases and abbreviated A, T, C, and G) that make up the DNA of the 24 different human chromosomes, was the greatest technical challenge in the Human Genome Project. Achieving this goal has helped reveal the estimated 20,000-25,000 human genes within our DNA as well as the regions controlling them. The resulting DNA sequence maps are being used by 21st Century scientists to explore human biology and other complex phenomena.Meeting Human Genome Project sequencing goals by 2003 required continual improvements in sequencing speed, reliability, and costs. Previously, standard methods were based on separating DNA fragments by gel electrophoresis, which was extremely labor intensive and expensive. Total sequencing output in the community was about 200 million base pairs for 1998. In January 2003, the DOE Joint Genome Institute alone sequenced 1.5 billion bases for the month.
Gel-based sequencers use multiple tiny (capillary) tubes to run standard electrophoretic separations. These separations are much faster because the tubes dissipate heat well and allow the use of much higher electric fields to complete sequencing in shorter times.
See a figure depicting this technology.




Whose genome was sequenced in the public (HGP) and private projects?

The human genome reference sequences do not represent any one person’s genome. Rather, they serve as a starting point for broad comparisons across humanity. The knowledge obtained from the sequences applies to everyone because all humans share the same basic set of genes and genomic regulatory regions that control the development and maintenance of their biological structures and processes.
In the international public-sector Human Genome Project (HGP), researchers collected blood (female) or sperm (male) samples from a large number of donors. Only a few samples were processed as DNA resources. Thus donors' identities were protected so neither they nor scientists could know whose DNA was sequenced. DNA clones from many libraries were used in the overall project.
Technically, it is much easier to prepare DNA cleanly from sperm than from other cell types because of the much higher ratio of DNA to protein in sperm and the much smaller volume in which purifications can be done. Sperm contain all chromosomes necessary for study, including equal numbers of cells with the X (female) or Y (male) sex chromosomes. However, HGP scientists also used white cells from female donors' blood to include samples originating from women.
In the Celera Genomics private-sector project, DNA from a few different genomes was mixed and processed for sequencing. DNA for these studies came from anonymous donors of European, African, American (North, Central, South), and Asian ancestry. The lead scientist of Celera Genomics at that time, Craig Venter, has since acknowledged that his DNA was among those sequenced.
Many polymorphisms—small regions of DNA that vary among individuals—also were identified during the HGP, mostly single nucleotide polymorphisms (SNPs). Most SNPs have no physiological effect, although a minority contribute to the beneficial diversity of humanity. A much smaller minority of polymorphisms affect an individual’s susceptibility to disease and response to medical treatments.
Although the HGP has been completed, SNP studies continue in the International HapMap Project, whose goal is to identify patterns of SNP groups (called haplotypes, or “haps”). The DNA samples for the HapMap Project came from 270 individuals, including Yoruba people in Ibadan, Nigeria; Japanese in Tokyo; Han Chinese in Beijing; and the French Centre d’Etude du Polymorphisme Humain (CEPH) resource.
[Answer supplied by Dr. Marvin Stodolsky, U.S. DOE Office of Biological and Environmental Research, Office of Science]



Who sequenced the human genome?

Human Genome Project research was funded at many laboratories across the U.S. by the Department of Energy (DOE), the National Institutes of Health (NIH), or both. A list of the major U.S. Human Genome Project research sites can be found here.Other researchers at numerous colleges, universities, and laboratories throughout the United States also have received DOE and NIH funding for human genome research. At any given time, the DOE Human Genome Project has funded about 100 principal investigators. For DOE-funded projects, see Research. To see a list of NIH-funded projects, visit the agency's grants database.
In addition, many large and small private U.S. companies are conducting genome research. For more on the genomics research partnership between the public and private sectors, see the Human Genome Project and the Private Sector Fact Sheet. At least 18 other countries have participated in the Human Genome Project. See the list.


How is DNA sequencing done?

Download a PDF illustration courtesy of the Department of Energy's Joint Genome Institute.
  • Chromosomes, which range in size from 50 million to 250 million bases, must first be broken into much shorter pieces (subcloning step).
  • Each short piece is used as a template to generate a set of fragments that differ in length from each other by a single base that will be identified in a later step (template preparation and sequencing reaction steps).See a figure depicting the sequencing reaction.
  • The fragments in a set are separated by gel electrophoresis (separation step).New fluorescent dyes allow separation of all four fragments in a single lane on the gel.
    See an example of an electropherogram using fluorescent dyes. Click on the image for a caption.
  • The final base at the end of each fragment is identified (base-calling step). This process recreates the original sequence of As, Ts, Cs, and Gs for each short piece generated in the first step.Automated sequencers analyze the resulting electropherograms, and the output is a four-color chromatogram showing peaks that represent each of the four DNA bases.
    After the bases are "read," computers are used to assemble the short sequences (in blocks of about 500 bases each, called the read length) into long continuous stretches that are analyzed for errors, gene-coding regions, and other characteristics.
    To read about all the trouble researchers go through to "finish" this raw sequence from automated sequencers, click here (and scroll to bottom that begins "Here are our definitions of . . . ").
    Finished sequences are submitted to major public sequence databases, such as GenBank. Human Genome Project sequence data are thus freely available to anyone around the world.



In May 2006, Human Genome Project (HGP) researchers announced the completion of the DNA sequence for the last of the 24 human chromosomes. How does this differ from the finished human genome announced by HGP researchers in 2003?

The DNA sequences announced in 2003 were only rough drafts for each human chromosome. While this draft already has advanced medical research, more detail was needed. The draft genomic sequences can be compared broadly to a cross-country road excavated by a bulldozer that leaves behind many gaps across difficult terrain that will require bridges and other refinements.
So, too, with charting the landscape of the human genome. Researchers have now filled in the gaps and provided far more detail for each chromosome. Much of this was accomplished by comparing particular DNA sequences across populations in genomic areas that may have contained anomalies in the initial samples. For example, some DNA segments have proven unstable during the process of copying them (cloning) for use in sequencing machines. (See an example.) Correcting minor errors (estimated at 1 error in every 10,000 DNA subunits) and cataloging of mutations will continue for some time to come.
The entire collection of human chromosome DNA sequences is freely available to the worldwide research community.
For more details, see the Nature HG Collection.


What is the difference between draft sequence and finished sequence?

In generating the draft sequence (released in June 2000), scientists determined the order of base pairs in each chromosomal area at least 4 to 5 times (4x to 5x) to ensure data accuracy and to help with reassembling DNA fragments in their original order. This repeated sequencing is known as genome "depth of coverage." Draft sequence data are mostly in the form of 10,000 base pair-sized fragments whose approximate chromosomal locations are known.
To generate a high-quality reference sequence, completed in April 2003, additional sequencing was done to close gaps, reduce ambiguities, and allow for only a single error every 10,000 bases, the agreed-upon standard for the HGP. Investigators believe a high-quality sequence is critical for recognizing gene-regulatory components important in understanding human biology and disorders such as heart disease, cancer, and diabetes. The finished version provides an estimated 8x to 9x coverage of each chromosome.


What genomes have been sequenced completely?

The small genomes of several viruses and bacteria and the much larger genomes of three higher organisms have been completely sequenced; they are bakers' or brewers' yeast (Saccharomyces cerevisiae), the roundworm (Caenorhabditis elegans), and the fruit fly (Drosophila melanogaster). In October 2001, the draft sequence of the pufferfish Fugu rubripes, the first vertebrate after the human, was completed; and scientists finished the first genetic sequence of a plant, that of the weed Arabidopsis thaliana, in December 2000. Many more genome sequences have been completed since then.For information on published and unpublished genomes, see Genomes Online Database (GOLD).



What nonhuman genome sequencing projects are supported by the U.S. Department of Energy?

A list of microbial genome sequencing projects supported by the U.S. Department of Energy Microbial Genome Program is available here.


What happens now that the human genome sequence is completed?

The working-draft DNA sequence and the more polished 2003 version represent an enormous achievement, akin in scientific importance, some say, to developing the periodic table of elements. And, as in most major scientific advances, much work remains to realize the full potential of the accomplishment.
Early explorations of the human genome, now joined by projects on the genomes of several other organisms, are generating data whose volume and complex analyses are unprecedented in biology. Genomic-scale technologies will be needed to study and compare entire genomes, sets of expressed RNAs or proteins, gene families from a large number of species, variation among individuals, and the classes of gene regulatory elements.
Deriving meaningful knowledge from DNA sequences will define biological research through the coming decades and require the expertise and creativity of teams of biologists, chemists, engineers, and computational scientists, among others. A sampling follows of some research challenges in genetics--what we still don't know, even with the full human DNA sequence in hand.
  • Gene number, exact locations, and functions
  • Gene regulation
  • DNA sequence organization
  • Chromosomal structure and organization
  • Noncoding DNA types, amount, distribution, information content, and functions
  • Coordination of gene expression, protein synthesis, and post-translational events
  • Interaction of proteins in complex molecular machines
  • Predicted vs experimentally determined gene function
  • Evolutionary conservation among organisms
  • Protein conservation (structure and function)
  • Proteomes (total protein content and function) in organisms
  • Correlation of SNPs (single-base DNA variations among individuals) with health and disease
  • Disease-susceptibility prediction based on gene sequence variation
  • Genes involved in complex traits and multigene diseases
  • Complex systems biology, including microbial consortia useful for environmental restoration
  • Developmental genetics, genomics

Posted in | Leave a comment